High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension

Journal of Human Hypertension

Volumn 27, Issue 4, 2013, Pages 225-230

  De Haro Moraes, C ^a   Figueiredo, V N ^a   De Faria, A P C ^a   Barbaro, N R ^a   Sabbatini, A R ^a   Quinaglia, T ^a   Ferreira Melo, S E ^a   Martins, L C ^a   Demacq, C ^a,b   Junior H M ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Novartis Biociencias SA   (Brazil)

Author keywords

aldosterone; leptin; obesity; resistant hypertension

Indexed keywords

ALDOSTERONE; LEPTIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GENDER; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE;

AGED; ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DRUG RESISTANCE; FEMALE; HEART RATE; HUMANS; HYPERTENSION; LEPTIN; LINEAR MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT FAILURE; UP-REGULATION;

EID: 84875225077     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2012.29     Document Type: Article

References (35)

1. Krousel-Wood M, Hyre A, Muntner P, Morisky D. Methods to improve medication adherence in patients with hypertension: current status and future directions. Curr Opin Cardiol 2005; 20(4): 296-300.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560-2572.
3. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51(6): 1403-1419.
4. Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press Monit 2003; 8(5): 181-185.
5. Gelber RP, Gaziano JM, Manson JE, Buring JE, Sesso HD. A prospective study of body mass index and the risk of developing hypertension in men. Am J Hypertens 2007; 20(4): 370-377.
6. Kotchen TA, Grim CE, Kotchen JM, Krishnaswami S, Yang H, Hoffmann RG et al. Altered relationship of blood pressure to adiposity in hypertension. Am J Hyper-tens 2008; 21(3): 284-289.
7. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150(11): 776-783.
8. Fonseca-Alaniz MH, Takada J, Alonso-Vale MI, Lima FB. Adipose tissue as an endocrine organ: from theory to practice. J Pediatr 2007; 83(5 Suppl): S192-S203.
9. Matsumura K, Tsuchihashi T, Fujii K, Iida M. Neural regulation of blood pressure by leptin and the related peptides. Regul Pept 2003; 114(2-3): 79-86.
10. da Silva AA, do Carmo J, Dubinion J, Hall JE. The role of the sympathetic q nervous system in obesity-related hypertension. Curr Hypertens Rep 2009; 11(3): 206-211.
11. Wannamethee SG, Tchernova J, Whincup P, Lowe GD, Kelly A, Rumley A et al. Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis 2007; 191(2): 418-426.
12. Singhal A, Farooqi IS, Cole TJ, O'Rahilly S, Fewtrell M, Kattenhorn M et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation 2002; 106(15): 1919-1924.
13. Ciccone M, Vettor R, Pannacciulli N, Minenna A, Bellacicco M, Rizzon P et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 2001; 25(6): 805-810.
14. Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF et al. Characteristics of resistant hypertension: ageing, body mass index, hyper-aldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens 2011; 25(9): 532-538.
15. de Souza WA, Yugar-Toledo JC, Bergsten-Mendes G, Sabha M, Moreno Jr H. Effect of pharmaceutical care on blood pressure control and health-related quality of life in patients with resistant hypertension. Am J Health Syst Pharm 2007; 64(18): 1955-1961.
16. Groppelli A, Omboni S, Parati G, Mancia G. Evaluation of noninvasive blood pressure monitoring devices Spacelabs 90202 and 90207 versus resting and ambulatory 24-hour intra-arterial blood pressure. Hypertension 1992; 20(2): 227-232.
17. Quehenberger P, Exner M, Sunder-Plassmann R, Ruzicka K, Bieglmayer C, Endler G et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res 2002; 90(6): 711-718.
18. Oda A, Taniguchi T, Yokoyama M. Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 2001; 47(3): 141-150.
19. Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999; 13(10): 1231-1238.
20. Shankar A, Xiao J. Positive relationship between plasma leptin level and hypertension. Hypertension 2010; 56(4): 623-628.
21. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371(9628): 1921-1926.
22. Hilzendeger AM, Morais RL, Todiras M, Plehm R, da Costa Goncalves A, Qadri F et al. Leptin regulates ACE activity in mice. J Mol Med 2010; 88(9): 899-907.
23. Ehrhart-Bornstein M, Arakelyan K, Krug AW, Scherbaum WA, Bornstein SR. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res 2004; 30(4): 865-870.
24. Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999; 79(1): 1-71.
25. Elmquist JK, Ahima RS, Maratos-Flier E, Flier JS, Saper CB. Leptin activates neurons in ventrobasal hypothalamus and brainstem. Endocrinology 1997; 138(2): 839-842.
26. Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev 2005; 10(1): 7-13.
27. Stas S, Whaley-Connell A, Habibi J, Appesh L, Hayden MR, Karuparthi PR et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007; 148(8): 3773-3780.
28. Kalil GZ, Haynes WG. Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertens Res 2012; 35(1)4-16.
29. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105(7): 804-809.
30. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54(3): 475-481.
31. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49(4): 839-845.
32. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008; 117(17): 2253-2261.
33. Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008; 31(1): 59-67.
34. Rahmouni K, Haynes WG, Morgan DA, Mark AL. Selective resistance to central neural administration of leptin in agouti obese mice. Hypertension 2002; 39(2, Part 2): 486-490.
35. Gomez R, Lago F, Gomez-Reino JJ, Gualillo O. Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin. Expert Opin Ther Targets 2009; 13(5): 583-591.